Ovid Therapeutics Inc. (OVID) stock forecast and price target
Price $2.54 · data as of November 13, 2026
12-month price target
Average target$6.15
Upside / downside+142.1%
Analysts10
ConsensusStrong buy
Low $4.00Average $6.15High $9.00
Gold marker: average target · white marker: today’s price ($2.54)
Analyst ratings
Strong buy 0Buy 13Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.40 | −73.9% | $810500 |
| Next fiscal year ends December 31, 2027 | $-0.40 | −1.1% | $258420 |
| Next quarter ends December 31, 2026 | $-0.08 | −240.7% | $66250 |
| Quarter after ends December 31, 2026 | $-0.10 | −270.8% | $16670 |
Consensus of the analysts covering Ovid Therapeutics, updated daily. In the last 30 days 7 estimates were raised and 0 lowered.
Frequently asked questions
What is the Ovid Therapeutics stock price target?
The average 12-month target from 10 analysts is $6.15, 142.1% above the current price of $2.54 Targets range from $4.00 to $9.00.
Is Ovid Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (13 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Ovid Therapeutics expected to earn?
Analysts expect EPS of $-0.40 for the fiscal year ending December 31, 2026 and $-0.40 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.